Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients Jane E LatzAjai ChaudharyRobert D Johnson Original Article 02 December 2005 Pages: 401 - 411
A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy Jane E LatzMats O KarlssonRobert D Johnson Original Article 02 December 2005 Pages: 412 - 426
Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy Jane E. LatzJames J. RusthovenRobert D. Johnson Original Article 02 December 2005 Pages: 427 - 435
Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma Seok Jin KimHee Yun SeoJun Suk Kim Original Article 28 July 2005 Pages: 436 - 442
Interpreting cell cycle effects of drugs: the case of melphalan Monica LupiPaolo CappellaPaolo Ubezio Original Article 30 September 2005 Pages: 443 - 457
A liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of actinomycin-D and vincristine in children with cancer Jeffrey M. SkolnikJeffrey S. BarrettPeter C. Adamson Original Article 27 September 2005 Pages: 458 - 464
Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers Ramesh K. RamanathanMarwan FakihMerrill J. Egorin Original Article 25 August 2005 Pages: 465 - 474
Development and validation of limited sampling models for topotecan lactone pharmacokinetic studies in children P. Kellie TurnerLisa C. IaconoClinton F. Stewart Original Article 27 July 2005 Pages: 475 - 482
Satraplatin activation by haemoglobin, cytochrome C and liver microsomes in vitro Jocelyn L CarrMalcolm D TingleMark J McKeage Original Article 20 September 2005 Pages: 483 - 490
Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells Maria SerovaFabien CalvoEric Raymond Original Article 02 August 2005 Pages: 491 - 499
Pharmacokinetics and phototoxicity of purpurin-18 in human colon carcinoma cells using liposomes as delivery vehicles Sulbha SharmaAlok DubePradeep K Gupta Original Article 02 August 2005 Pages: 500 - 506
Apoptosis induced by glycoprotein (150-kDa) isolated from Solanum nigrum L. is not related to intracellular reactive oxygen species (ROS) in HCT-116 cells Sei-Jung LeeKye-Taek Lim Original Article 06 October 2005 Pages: 507 - 516
Effect of amifostine on the cytotoxicity of daunorubicin and daunoxome in tumor and normal cells Michelutti AngelaStocchi RaffaellaDamiani Daniela Original Article 05 July 2005 Pages: 517 - 524
Antiproliferation and radiosensitization of caffeic acid phenethyl ester on human medulloblastoma cells Yi-Hsien LinJen-Hwey ChiuSang-Hue Yen Original Article 20 September 2005 Pages: 525 - 532
A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma Monika JermannRolf A StahelMiklos Pless Original Article 29 July 2005 Pages: 533 - 539
Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer Silwan ChedidEdgardo RiveraMassimo Cristofanilli Original Article 29 September 2005 Pages: 540 - 544